bodwd11

Property	Value
?:abstract	Background: The coronavirus disease 2019 (COVID-19) pandemic is rapidly expanding across the world, with more than 100,000 new cases each day as of end-June 2020 Healthcare workers are struggling to provide the best care for COVID-19 patients Approaches for invasive ventilation vary widely between and within countries and new insights are acquired rapidly We aim to investigate invasive ventilation practices and outcome in COVID-19 patients in the Netherlands Methods: PRoVENT-COVID (\'study of PRactice of VENTilation in COVID-19\') is an investigator-initiated national, multicenter observational study to be undertaken in intensive care units (ICUs) in The Netherlands Consecutive COVID-19 patients aged 18 years or older, who are receiving invasive ventilation in the participating ICUs, are to be enrolled during a 10-week period, with a daily follow-up of 7 days The primary outcome is ventilatory management (including tidal volume expressed as mL/kg predicted body weight and positive end-expiratory pressure expressed as cmH2O) during the first 3 days of ventilation Secondary outcomes include other ventilatory variables, use of rescue therapies for refractory hypoxemia such as prone positioning and extracorporeal membrane oxygenation, use of sedatives, vasopressors and inotropes;daily cumulative fluid balances;acute kidney injury;ventilator-free days and alive at day 28 (VFD-28), duration of ICU and hospital stay, and ICU, hospital and 90-day mortality Discussion: PRoVENT-COVID will be the largest observational study to date, with high density ventilatory data and major outcomes There is urgent need for a better understanding of ventilation practices, and the effects of ventilator settings on outcomes in COVID-19 patients The results of PRoVENT-COVID will be rapidly disseminated through electronic presentations, such as webinars and electronic conferences, and publications in international peer-reviewed journals Access to source data will be made available through local, regional and national anonymized datasets on request, and after agreement of the PRoVENT-COVID steering committee Trial Registration: PRoVENT-COVID is registered at clinicaltrials gov (identifier NCT04346342) Background: The coronavirus disease 2019 (COVID-19) pandemic is rapidly expanding across the world, with more than 100,000 new cases each day as of end-June 2020. Healthcare workers are struggling to provide the best care for COVID-19 patients. Approaches for invasive ventilation vary widely between and within countries and new insights are acquired rapidly. We aim to investigate invasive ventilation practices and outcome in COVID-19 patients in the Netherlands. Methods: PRoVENT-COVID (\'study of PRactice of VENTilation in COVID-19\') is an investigator-initiated national, multicenter observational study to be undertaken in intensive care units (ICUs) in The Netherlands. Consecutive COVID-19 patients aged 18 years or older, who are receiving invasive ventilation in the participating ICUs, are to be enrolled during a 10-week period, with a daily follow-up of 7 days. The primary outcome is ventilatory management (including tidal volume expressed as mL/kg predicted body weight and positive end-expiratory pressure expressed as cmH2O) during the first 3 days of ventilation. Secondary outcomes include other ventilatory variables, use of rescue therapies for refractory hypoxemia such as prone positioning and extracorporeal membrane oxygenation, use of sedatives, vasopressors and inotropes; daily cumulative fluid balances; acute kidney injury; ventilator-free days and alive at day 28 (VFD-28), duration of ICU and hospital stay, and ICU, hospital and 90-day mortality. Discussion: PRoVENT-COVID will be the largest observational study to date, with high density ventilatory data and major outcomes. There is urgent need for a better understanding of ventilation practices, and the effects of ventilator settings on outcomes in COVID-19 patients. The results of PRoVENT-COVID will be rapidly disseminated through electronic presentations, such as webinars and electronic conferences, and publications in international peer-reviewed journals. Access to source data will be made available through local, regional and national anonymized datasets on request, and after agreement of the PRoVENT-COVID steering committee. Trial Registration: PRoVENT-COVID is registered at clinicaltrials.gov (identifier NCT04346342).
is ?:annotates of	<https://research.tib.eu/covid-19/entity/4bodwd11_hasAnnotation_C0027627> <https://research.tib.eu/covid-19/entity/4bodwd11_hasAnnotation_C0036557> <https://research.tib.eu/covid-19/entity/4bodwd11_hasAnnotation_C0042397>
?:creator	<https://research.tib.eu/covid-19/entity/Boers%2C_N._S.%3B_Botta%2C_M.%3B_Tsonas%2C_A._M.%3B_Algera%2C_A._G.%3B_Pillay%2C_J.%3B_Dongelmans%2C_D._A.%3B_Horn%2C_J.%3B_Vlaar%2C_A._P._J.%3B_Hollmann%2C_M._W.%3B_Bos%2C_L._D._J.%3B_Paulus%2C_F.%3B_Neto%2C_A._S.%3B_Schultz%2C_M._J.%3B_investigators%2C_P._RoVENT-COVID> <https://research.tib.eu/covid-19/entity/Boers%2C_Noor_S%3B_Botta%2C_Michela%3B_Tsonas%2C_Annisa_M%3B_Algera%2C_Anna_Geke%3B_Pillay%2C_Janesh%3B_Dongelmans%2C_Dave_A%3B_Horn%2C_Janneke%3B_Vlaar%2C_Alexander_P_J%3B_Hollmann%2C_Markus_W%3B_Bos%2C_Lieuwe_D_J%3B_Paulus%2C_Frederique%3B_Neto%2C_Ary_Serpa%3B_Schultz%2C_Marcus_J>
?:journal	Ann_Transl_Med Annals_of_Translational_Medicine
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:source	WHO
?:title	PRactice of VENTilation in Patients with Novel Coronavirus Disease (PRoVENT-COVID): rationale and protocol for a national multicenter observational study in The Netherlands
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#921328 #994852
?:year	2020

Property

Value

?:abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic is rapidly expanding across the world, with more than 100,000 new cases each day as of end-June 2020 Healthcare workers are struggling to provide the best care for COVID-19 patients Approaches for invasive ventilation vary widely between and within countries and new insights are acquired rapidly We aim to investigate invasive ventilation practices and outcome in COVID-19 patients in the Netherlands Methods: PRoVENT-COVID (\'study of PRactice of VENTilation in COVID-19\') is an investigator-initiated national, multicenter observational study to be undertaken in intensive care units (ICUs) in The Netherlands Consecutive COVID-19 patients aged 18 years or older, who are receiving invasive ventilation in the participating ICUs, are to be enrolled during a 10-week period, with a daily follow-up of 7 days The primary outcome is ventilatory management (including tidal volume expressed as mL/kg predicted body weight and positive end-expiratory pressure expressed as cmH2O) during the first 3 days of ventilation Secondary outcomes include other ventilatory variables, use of rescue therapies for refractory hypoxemia such as prone positioning and extracorporeal membrane oxygenation, use of sedatives, vasopressors and inotropes;daily cumulative fluid balances;acute kidney injury;ventilator-free days and alive at day 28 (VFD-28), duration of ICU and hospital stay, and ICU, hospital and 90-day mortality Discussion: PRoVENT-COVID will be the largest observational study to date, with high density ventilatory data and major outcomes There is urgent need for a better understanding of ventilation practices, and the effects of ventilator settings on outcomes in COVID-19 patients The results of PRoVENT-COVID will be rapidly disseminated through electronic presentations, such as webinars and electronic conferences, and publications in international peer-reviewed journals Access to source data will be made available through local, regional and national anonymized datasets on request, and after agreement of the PRoVENT-COVID steering committee Trial Registration: PRoVENT-COVID is registered at clinicaltrials gov (identifier NCT04346342)
Background: The coronavirus disease 2019 (COVID-19) pandemic is rapidly expanding across the world, with more than 100,000 new cases each day as of end-June 2020. Healthcare workers are struggling to provide the best care for COVID-19 patients. Approaches for invasive ventilation vary widely between and within countries and new insights are acquired rapidly. We aim to investigate invasive ventilation practices and outcome in COVID-19 patients in the Netherlands. Methods: PRoVENT-COVID (\'study of PRactice of VENTilation in COVID-19\') is an investigator-initiated national, multicenter observational study to be undertaken in intensive care units (ICUs) in The Netherlands. Consecutive COVID-19 patients aged 18 years or older, who are receiving invasive ventilation in the participating ICUs, are to be enrolled during a 10-week period, with a daily follow-up of 7 days. The primary outcome is ventilatory management (including tidal volume expressed as mL/kg predicted body weight and positive end-expiratory pressure expressed as cmH2O) during the first 3 days of ventilation. Secondary outcomes include other ventilatory variables, use of rescue therapies for refractory hypoxemia such as prone positioning and extracorporeal membrane oxygenation, use of sedatives, vasopressors and inotropes; daily cumulative fluid balances; acute kidney injury; ventilator-free days and alive at day 28 (VFD-28), duration of ICU and hospital stay, and ICU, hospital and 90-day mortality. Discussion: PRoVENT-COVID will be the largest observational study to date, with high density ventilatory data and major outcomes. There is urgent need for a better understanding of ventilation practices, and the effects of ventilator settings on outcomes in COVID-19 patients. The results of PRoVENT-COVID will be rapidly disseminated through electronic presentations, such as webinars and electronic conferences, and publications in international peer-reviewed journals. Access to source data will be made available through local, regional and national anonymized datasets on request, and after agreement of the PRoVENT-COVID steering committee. Trial Registration: PRoVENT-COVID is registered at clinicaltrials.gov (identifier NCT04346342).

is ?:annotates of

?:creator

?:journal

Ann_Transl_Med
Annals_of_Translational_Medicine

?:license

?:publication_isRelatedTo_Disease

<https://research.tib.eu/covid-19/entity/COVID-19>

?:source

?:title

PRactice of VENTilation in Patients with Novel Coronavirus Disease (PRoVENT-COVID): rationale and protocol for a national multicenter observational study in The Netherlands

?:type